Does Syndax Pharmaceuticals (SNDX) Pay a Dividend? (2026)

No. Syndax Pharmaceuticals has no dividend on record, so the yield is 0% and holding SNDX produces no income. Syndax Pharmaceuticals is not consistently profitable yet (net loss of $49.4M, or $0.55 per share, in 2Q26 versus $71.8M and $0.83 a year earlier; $92.0M and $1.04 per share for the first half of 2026 versus $156.7M and $1.82. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. Operating loss narrowed to $40.0M in 2Q26 from $69.4M. There is no P/E, and there has never been an annual profit.), and companies do not usually start returning cash before earnings are durable. Every dollar of return from SNDX has to come from the share price. Verify the current policy on SNDX's investor relations page, since a board can start a dividend at any time.

Syndax Pharmaceuticals is not consistently profitable yet (net loss of $49.4M, or $0.55 per share, in 2Q26 versus $71.8M and $0.83 a year earlier; $92.0M and $1.04 per share for the first half of 2026 versus $156.7M and $1.82. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. Operating loss narrowed to $40.0M in 2Q26 from $69.4M. There is no P/E, and there has never been an annual profit.), and companies do not usually start returning cash before earnings are durable. Its free cash flow position (cash, cash equivalents and short and long-term investments of $575.1M at June 30, 2026, up from $394.1M at December 31, 2025 after the $250M convertible issue. Operating cash burn fell to $80.6M in the first half of 2026 from $183.0M a year earlier. Total assets $703.7M, total liabilities $688.6M (including a $344.0M royalty interest financing liability and a $244.1M convertible note liability) and stockholders' equity of just $15.1M. Accumulated deficit ~$1.6B.) is the constraint that matters most here: a dividend is a standing commitment, and starting one before cash generation is reliable would mean funding it from the balance sheet. Paying nothing is a deliberate choice, not a failure. A growth company that can reinvest at high returns creates more value per dollar retained than it would by handing that dollar to shareholders.

Nobody can say, and we will not guess. What usually has to happen first is a stretch of durable profitability and positive free cash flow, with enough left over after reinvestment that the company runs out of better uses for the money. Watch for those in the quarterly results rather than for an announcement. Companies also often start with buybacks before a dividend, because a buyback carries no ongoing commitment.

0%. There is no dividend, so there is no yield. This matters for planning: if you are building an income portfolio, SNDX contributes nothing to the income side and its entire contribution is price return. It also means the position generates no taxable income while you hold it.

The usual approach is to pair a non-payer like SNDX with holdings that do pay: dividend stocks, dividend ETFs, or bond funds, sized so the income side of the portfolio meets your needs while the growth side stays intact. Some investors sell covered calls on positions they hold, though that caps the upside that is the whole reason to own a growth name. See our guides to the best dividend stocks and best dividend ETFs. Walnut is not an investment adviser.

Not while you hold it. With no dividend there is no income to report, so nothing is taxable until you sell. At that point you owe capital-gains tax on the gain, at long-term rates if you held for more than a year and at ordinary-income rates if you did not. That deferral is a genuine, if minor, advantage of non-payers in a taxable account. This is not tax advice.

It is the wrong tool for that job, which is not the same as a bad company. If you need cash from your portfolio, a stock paying nothing forces you to sell shares to generate it, which means selling into whatever price the market happens to offer. Investors who want SNDX's growth exposure and also want income typically hold both, rather than expecting one holding to do both jobs.

No. Syndax has never paid a dividend and does not currently generate net income, so there is no distributable profit. The company is spending roughly $400M a year on research and selling costs against ~$252M of trailing revenue and is funding the gap from a $575.1M cash and investments balance built partly from a $350M royalty monetisation and $250M of convertible notes. Both of those instruments carry claims that rank ahead of shareholders: the notes pay 2.25% semi-annual cash interest, and Royalty Pharma takes 13.8% of US Niktimvo net sales up to an $822.5M cap. Companies at this stage of a launch generally reinvest any surplus into trials rather than returning it, and Syndax's stated priority is reaching profitability rather than distributions.